Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M …
WEB1 day ago · The deal amount represents 5.8% of Yuhan’s latest yearly sales of 1.85 trillion Korean won ($1.4 billion), according to a filing. Yuhan co-promotes several Gilead HIV drugs, including the ...
Yuhan inks $80.9M deal with Gilead Sciences for HIV drug …
WEB1 day ago · Yuhan has secured an $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human immunodeficiency virus (HIV), the Korean drugmaker announced in an electronic disclosure on Friday. The contract runs through Sept. 30, 2025, according to the regulatory filing.
Yuhan, Janssen halt next-gen cancer drug collaboration - The …
WEB1 day ago · Yuhan's corporate logo (Yuhan) South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the development of a next-generation targeted ...
Yuhan inks $81 mn contract with U.S. Gilead to supply HIV …
WEB1 day ago · South Korean pharmaceutical company Yuhan Corp. announced on Friday that it has signed a contract with U.S. biopharmaceutical company Gilead Sciences Inc. to supply raw materials for human immunodeficiency virus (HIV) treatments. The contract is worth 107.6 billion won ($80.8 million), which is 5.79 percent of Yuhan’s sales in 2023.
Yuhan set to receive $60 m from Janssen for ... - 조선일보
WEBSep 12, 2024 · Yuhan Corporation announced on Sep 11., via a regulatory filing, that it will receive a $60 million (about 80.4 billion won) milestone payment from Janssen Biotech, a subsidiary of Johnson & Johnson, following the successful commercialization of its out-licensed anticancer drug, Lazertinib (marketed in Korea as Leclaza).
Yuhan Shares Jump 4% After US FDA Approves Anti-Cancer Drug …
WEBAug 21, 2024 · Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. -- Shares of Yuhan jumped more than 4% in recent trade after the U.S. Food and Drug Administration approved RYBREVANT, or amivantamab-vmjw plus LAZCLUZE, or lazertinib, for patients suffering from...
Yuhan eyes next Leclaza with R&D, open innovation after U.S.
WEBAug 23, 2024 · Following the U.S. approval of lung treatment Leclaza, Korea’s first cancer drug to achieve the milestone, Yuhan Corporation is now seeking the next breakthrough with a renewed focus on research and development (R&D).
Yuhan nabs Ubix cancer drug for ₩150B; YH-35995 trial cleared
WEBJul 1, 2024 · Yuhan Corp., of Seoul, South Korea, has inked a ₩150 billion (US$108.6 million) deal with Korean biotech Ubix Therapeutics Inc. to gain exclusive global rights to UBX-103, Ubix’s oral small-molecule androgen receptor (AR) degrader for prostate cancer.
Yuhan Corporation and J INTS BIO inked a licensing agreement …
WEBSEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a...
Yuhan to pay ₩208B for Cyrus-Kanaph’s SOS1 inhibitor for cancer
WEBMar 8, 2024 · Yuhan Corp., of Seoul, South Korea, added a new potential cancer drug to its oncology pipeline, licensing a son of sevenless homolog 1 (SOS1) inhibitor co-developed by Cyrus Therapeutics Inc. and Kanaph Therapeutics Inc. for ₩208 billion (US$156.3 million).
Skip to content